{"hands_on_practices": [{"introduction": "A key principle in pharmacology is exploiting the unique physiology of a pathogen. This practice explores the mechanism of ion trapping, a phenomenon where a drug accumulates to high concentrations within a specific cellular compartment. You will use the fundamental Henderson-Hasselbalch relation to derive how the antimalarial drug chloroquine, a weak base, becomes concentrated in the acidic digestive vacuole of the malaria parasite, a critical step for its therapeutic action [@problem_id:4649129].", "problem": "A central feature of the mechanism of action of the antiparasitic drug chloroquine is its accumulation in the acidic digestive vacuole of the malaria parasite, where it interferes with heme detoxification. Chloroquine is a diprotic weak base with two sequential protonation steps, and only its neutral form permeates the vacuolar membrane; protonated forms are effectively membrane-impermeant and become trapped. Starting from the Henderson–Hasselbalch (HH) relation and mass-action equilibria for a diprotic base, derive an expression for the ratio of total chloroquine concentration in the vacuole to that in the cytosol as a function of the vacuolar pH, cytosolic pH, and the two acid dissociation constants of its conjugate acids. Assume:\n- Only the neutral base, denoted by $B$, can cross the membrane and therefore satisfies $[B]_{\\text{vacuole}} = [B]_{\\text{cytosol}}$ at equilibrium.\n- The two protonation equilibria are $BH^{+} \\rightleftharpoons B + H^{+}$ with acid dissociation constant $K_{a1}$ and $BH_{2}^{2+} \\rightleftharpoons BH^{+} + H^{+}$ with acid dissociation constant $K_{a2}$.\n- The Henderson–Hasselbalch (HH) relation applies in each compartment for both protonation steps.\n\nThen, using $pK_{a1} = 8.1$, $pK_{a2} = 10.2$, a vacuolar pH of $5.0$, and a cytosolic pH of $7.2$, evaluate your derived expression to predict the vacuole-to-cytosol total concentration ratio. Express the final ratio as a pure number, and round your answer to four significant figures.", "solution": "The problem is scientifically grounded, well-posed, objective, and contains sufficient, consistent information for a unique solution. Therefore, it is valid. The following solution is derived based on the provided principles and data.\n\nLet $B$ represent the neutral form of the diprotic weak base chloroquine. Let $BH^{+}$ be its singly protonated form and $BH_{2}^{2+}$ be its doubly protonated form. The total concentration of chloroquine, $[C]_{\\text{total}}$, in any compartment is the sum of the concentrations of all its forms:\n$$[C]_{\\text{total}} = [B] + [BH^{+}] + [BH_{2}^{2+}]$$\n\nThe problem provides the acid dissociation equilibria and their corresponding constants:\n1.  $BH^{+} \\rightleftharpoons B + H^{+}$ with a constant $K_{a1}$. The law of mass action for this equilibrium is:\n    $$K_{a1} = \\frac{[B][H^{+}]}{[BH^{+}]}$$\n2.  $BH_{2}^{2+} \\rightleftharpoons BH^{+} + H^{+}$ with a constant $K_{a2}$. The law of mass action for this equilibrium is:\n    $$K_{a2} = \\frac{[BH^{+}][H^{+}]}{[BH_{2}^{2+}]}$$\n\nWe can express the concentrations of the protonated forms, $[BH^{+}]$ and $[BH_{2}^{2+}]$, in terms of the neutral form, $[B]$, and the proton concentration, $[H^{+}]$. Rearranging the equilibrium expressions:\nFrom the first equilibrium:\n$$[BH^{+}] = \\frac{[B][H^{+}]}{K_{a1}}$$\nFrom the second equilibrium:\n$$[BH_{2}^{2+}] = \\frac{[BH^{+}][H^{+}]}{K_{a2}}$$\nSubstituting the expression for $[BH^{+}]$ into the equation for $[BH_{2}^{2+}]$:\n$$[BH_{2}^{2+}] = \\frac{1}{K_{a2}} \\left( \\frac{[B][H^{+}]}{K_{a1}} \\right) [H^{+}] = \\frac{[B][H^{+}]^2}{K_{a1}K_{a2}}$$\n\nNow, we substitute these expressions for $[BH^{+}]$ and $[BH_{2}^{2+}]$ into the equation for the total concentration:\n$$[C]_{\\text{total}} = [B] + \\frac{[B][H^{+}]}{K_{a1}} + \\frac{[B][H^{+}]^2}{K_{a1}K_{a2}}$$\nFactoring out $[B]$, we obtain a general expression for the total concentration in a given compartment:\n$$[C]_{\\text{total}} = [B] \\left( 1 + \\frac{[H^{+}]}{K_{a1}} + \\frac{[H^{+}]^2}{K_{a1}K_{a2}} \\right)$$\nThis verifies that the total concentration is a function of the local proton concentration $[H^{+}]$ and the concentration of the neutral base $[B]$.\n\nThe goal is to find the ratio $R$ of the total chloroquine concentration in the vacuole to that in the cytosol:\n$$R = \\frac{[C]_{\\text{total, vacuole}}}{[C]_{\\text{total, cytosol}}}$$\nApplying the general expression to each compartment:\n$$R = \\frac{[B]_{\\text{vacuole}} \\left( 1 + \\frac{[H^{+}]_{\\text{vacuole}}}{K_{a1}} + \\frac{([H^{+}]_{\\text{vacuole}})^2}{K_{a1}K_{a2}} \\right)}{[B]_{\\text{cytosol}} \\left( 1 + \\frac{[H^{+}]_{\\text{cytosol}}}{K_{a1}} + \\frac{([H^{+}]_{\\text{cytosol}})^2}{K_{a1}K_{a2}} \\right)}$$\nThe problem states that only the neutral form $B$ can cross the membrane, which leads to the equilibrium condition $[B]_{\\text{vacuole}} = [B]_{\\text{cytosol}}$. This allows us to cancel these terms:\n$$R = \\frac{1 + \\frac{[H^{+}]_{\\text{vacuole}}}{K_{a1}} + \\frac{([H^{+}]_{\\text{vacuole}})^2}{K_{a1}K_{a2}}}{1 + \\frac{[H^{+}]_{\\text{cytosol}}}{K_{a1}} + \\frac{([H^{+}]_{\\text{cytosol}})^2}{K_{a1}K_{a2}}}$$\nTo facilitate calculation using the given $pH$ and $pK_a$ values, we use the relationships $pH = -\\log_{10}([H^{+}])$ and $pK_a = -\\log_{10}(K_a)$. These imply $[H^{+}] = 10^{-pH}$ and $K_a = 10^{-pK_a}$. The ratios in the expression can be rewritten as:\n$$\\frac{[H^{+}]}{K_{a1}} = \\frac{10^{-pH}}{10^{-pK_{a1}}} = 10^{pK_{a1} - pH}$$\n$$\\frac{[H^{+}]^2}{K_{a1}K_{a2}} = \\frac{(10^{-pH})^2}{(10^{-pK_{a1}})(10^{-pK_{a2}})} = \\frac{10^{-2 \\cdot pH}}{10^{-(pK_{a1}+pK_{a2})}} = 10^{pK_{a1} + pK_{a2} - 2 \\cdot pH}$$\nSubstituting these into the expression for $R$ yields the desired formula in terms of $pH$ and $pK_a$:\n$$R = \\frac{1 + 10^{pK_{a1} - pH_{\\text{vacuole}}} + 10^{pK_{a1} + pK_{a2} - 2 \\cdot pH_{\\text{vacuole}}}}{1 + 10^{pK_{a1} - pH_{\\text{cytosol}}} + 10^{pK_{a1} + pK_{a2} - 2 \\cdot pH_{\\text{cytosol}}}}$$\n\nNow, we evaluate this expression using the provided numerical values:\n- $pK_{a1} = 8.1$\n- $pK_{a2} = 10.2$\n- $pH_{\\text{vacuole}} = 5.0$\n- $pH_{\\text{cytosol}} = 7.2$\n\nFirst, calculate the numerator (vacuole term):\n$$N = 1 + 10^{8.1 - 5.0} + 10^{8.1 + 10.2 - 2 \\cdot (5.0)}$$\n$$N = 1 + 10^{3.1} + 10^{18.3 - 10.0}$$\n$$N = 1 + 10^{3.1} + 10^{8.3}$$\n\nNext, calculate the denominator (cytosol term):\n$$D = 1 + 10^{8.1 - 7.2} + 10^{8.1 + 10.2 - 2 \\cdot (7.2)}$$\n$$D = 1 + 10^{0.9} + 10^{18.3 - 14.4}$$\n$$D = 1 + 10^{0.9} + 10^{3.9}$$\n\nNow, we compute the numerical values:\n$$N = 1 + 10^{3.1} + 10^{8.3} \\approx 1 + 1258.925 + 199526231.497$$\n$$N \\approx 199527490.42$$\n$$D = 1 + 10^{0.9} + 10^{3.9} \\approx 1 + 7.9433 + 7943.2823$$\n$$D \\approx 7952.2256$$\n\nThe ratio $R$ is:\n$$R = \\frac{N}{D} \\approx \\frac{199527490.42}{7952.2256} \\approx 25090.64$$\n\nRounding the result to four significant figures as requested:\n$$R \\approx 25090$$\n\nThis substantial accumulation ratio, driven by the $pH$ gradient between the cytosol and the acidic vacuole, illustrates the principle of ion trapping, which is central to chloroquine's efficacy as an antimalarial drug.", "answer": "$$\\boxed{25090}$$", "id": "4649129"}, {"introduction": "Beyond accumulating in the right place, a drug must effectively engage its molecular target. This exercise delves into the pharmacodynamics of target inhibition, focusing on how albendazole disrupts parasite microtubules. By applying the law of mass action and the concept of a dissociation constant ($K_d$), you will quantify the relationship between drug concentration, target occupancy, and the resulting functional impairment of a vital cellular process, providing a concrete link between molecular binding and therapeutic effect [@problem_id:4649160].", "problem": "Albendazole binds to the parasite protein $\\beta$-tubulin and inhibits microtubule polymerization. Consider a simplified equilibrium model in which albendazole ($D$) binds to $\\beta$-tubulin ($T$) in a $1:1$ complex ($TD$), and only unbound $\\beta$-tubulin ($T$) can incorporate into growing microtubules. Assume steady state and that the free drug concentration is maintained at $200$ nM by the extracellular medium. The dissociation constant is given as $K_{d} = 50$ nM for the albendazole–$\\beta$-tubulin interaction. Use the law of mass action and the definition of the dissociation constant $K_{d}$, which at equilibrium satisfies $K_{d} \\equiv \\frac{[T][D]}{[TD]}$, and assume a homogeneous population of binding sites without cooperativity. In addition, assume that the instantaneous microtubule polymerization velocity is directly proportional to the concentration of free $\\beta$-tubulin relative to the no-drug baseline, and that albendazole-bound $\\beta$-tubulin is kinetically inactive for polymerization.\n\nBased on these principles, calculate the fraction of $\\beta$-tubulin sites occupied by albendazole at $[D] = 200$ nM and $K_{d} = 50$ nM, then determine the normalized microtubule polymerization velocity (relative to the no-drug baseline) implied by the fraction of free $\\beta$-tubulin. Express the final answer as the unitless normalized polymerization velocity, and round your final answer to three significant figures.", "solution": "The problem requires the calculation of the normalized microtubule polymerization velocity under the influence of the drug albendazole. This can be solved by applying the principles of chemical equilibrium and receptor binding theory.\n\nFirst, we formalize the components of the system. Let $D$ represent albendazole, $T$ represent free $\\beta$-tubulin, and $TD$ represent the albendazole-$\\beta$-tubulin complex. The concentrations of these species are denoted by $[D]$, $[T]$, and $[TD]$, respectively. The total concentration of $\\beta$-tubulin, $[T]_{\\text{total}}$, is the sum of its free and bound forms:\n$$ [T]_{\\text{total}} = [T] + [TD] $$\n\nThe problem states that the binding interaction follows the law of mass action and is characterized by a dissociation constant, $K_d$, defined as:\n$$ K_d = \\frac{[T][D]}{[TD]} $$\nThe given values are a constant free drug concentration of $[D] = 200$ nM and a dissociation constant of $K_d = 50$ nM.\n\nThe first step is to determine the fraction of $\\beta$-tubulin sites occupied by albendazole. This fraction, denoted by $\\theta$, is the ratio of the concentration of the bound complex $[TD]$ to the total tubulin concentration $[T]_{\\text{total}}$.\n$$ \\theta = \\frac{[TD]}{[T]_{\\text{total}}} = \\frac{[TD]}{[T] + [TD]} $$\nTo express $\\theta$ in terms of the known quantities $[D]$ and $K_d$, we first rearrange the dissociation constant equation to express $[T]$ in terms of $[TD]$:\n$$ [T] = \\frac{K_d [TD]}{[D]} $$\nNow, we substitute this expression for $[T]$ into the denominator of the equation for $\\theta$:\n$$ \\theta = \\frac{[TD]}{\\frac{K_d [TD]}{[D]} + [TD]} $$\nThe term $[TD]$ is common to all terms in the fraction and can be canceled out:\n$$ \\theta = \\frac{1}{\\frac{K_d}{[D]} + 1} $$\nMultiplying the numerator and denominator by $[D]$ gives the standard Hill-Langmuir equation for a $1:1$ binding equilibrium:\n$$ \\theta = \\frac{[D]}{K_d + [D]} $$\n\nUsing the provided numerical values, we calculate the fraction of occupied sites:\n$$ \\theta = \\frac{200 \\text{ nM}}{50 \\text{ nM} + 200 \\text{ nM}} = \\frac{200}{250} = \\frac{4}{5} = 0.8 $$\nThis means that at a steady-state drug concentration of $200$ nM, $80\\%$ of the $\\beta$-tubulin protein is bound to albendazole.\n\nThe problem states that the microtubule polymerization velocity, $v$, is directly proportional to the concentration of free $\\beta$-tubulin, $[T]$. We can write this relationship as $v = c[T]$, where $c$ is a constant of proportionality.\nThe baseline velocity, $v_0$, occurs in the absence of the drug (i.e., $[D] = 0$). In this no-drug condition, all tubulin is free, so the concentration of free tubulin is $[T]_{\\text{total}}$. Thus, the baseline velocity is $v_0 = c[T]_{\\text{total}}$.\n\nThe normalized polymerization velocity is the ratio of the velocity with the drug to the baseline velocity without the drug:\n$$ \\text{Normalized Velocity} = \\frac{v}{v_0} = \\frac{c[T]}{c[T]_{\\text{total}}} = \\frac{[T]}{[T]_{\\text{total}}} $$\nThis ratio is the fraction of $\\beta$-tubulin that is free (unbound). Since any tubulin molecule is either free or bound, the sum of the free fraction and the bound fraction must equal $1$. The bound fraction is $\\theta$.\n$$ \\frac{[T]}{[T]_{\\text{total}}} + \\frac{[TD]}{[T]_{\\text{total}}} = 1 $$\n$$ \\frac{[T]}{[T]_{\\text{total}}} + \\theta = 1 $$\nTherefore, the fraction of free tubulin is $1 - \\theta$.\n$$ \\text{Normalized Velocity} = 1 - \\theta $$\nUsing our calculated value for $\\theta$:\n$$ \\text{Normalized Velocity} = 1 - 0.8 = 0.2 $$\n\nAlternatively, we can express the normalized velocity using the fundamental parameters $K_d$ and $[D]$:\n$$ \\text{Normalized Velocity} = 1 - \\frac{[D]}{K_d + [D]} = \\frac{(K_d + [D]) - [D]}{K_d + [D]} = \\frac{K_d}{K_d + [D]} $$\nPlugging in the given values confirms the result:\n$$ \\text{Normalized Velocity} = \\frac{50 \\text{ nM}}{50 \\text{ nM} + 200 \\text{ nM}} = \\frac{50}{250} = \\frac{1}{5} = 0.2 $$\n\nThe problem requires the final answer to be rounded to three significant figures. The value $0.2$, when expressed to three significant figures, is $0.200$. This result implies that the presence of $200$ nM albendazole reduces the microtubule polymerization velocity to $20\\%$ of its normal rate.", "answer": "$$\\boxed{0.200}$$", "id": "4649160"}, {"introduction": "This final practice bridges fundamental principles with clinical application, demonstrating how molecular knowledge guides treatment strategies and combats drug resistance. You will act as a clinical microbiologist, integrating parasite genetic data (resistance mutations) with pharmacodynamic parameters ($K_i$) and pharmacokinetic constraints ($C_{max}$) to make a rational therapeutic choice. This case-based problem illustrates the power of molecular diagnostics in personalized medicine for infectious diseases, ensuring the selection of an effective regimen while avoiding predictable treatment failures [@problem_id:4649201].", "problem": "A patient with uncomplicated Plasmodium falciparum malaria is genotyped before therapy. Polymerase chain reaction (PCR) identifies the following point mutations in Plasmodium falciparum dihydrofolate reductase (pfDHFR): N$51$I, C$59$R, and S$108$N, with I$164$L absent. Plasmodium falciparum cytochrome b (pfCYTb) is wild-type at Y$268$ (i.e., Y$268$S absent). Kelch $13$ (K$13$) is wild-type (no C$580$Y), and Plasmodium falciparum multidrug resistance $1$ (pfMDR$1$) copy number is $1$ (no amplification). The clinical team seeks to avoid treatment failure and minimize toxicity.\n\nUse the following foundational bases to reason:\n- The Central Dogma of Molecular Biology states that mutations in genes encoding enzymes can alter amino acid sequence and thereby modify protein active sites, changing small-molecule binding affinity without abolishing essential catalytic function.\n- In competitive inhibition of an enzyme by a drug, inhibitor occupancy of the binding site increases with inhibitor concentration and decreases with the inhibitor dissociation constant. A simple binding model gives the fraction of enzyme bound by inhibitor as $f = \\dfrac{C}{C + K_i}$, where $C$ is inhibitor concentration and $K_i$ is the inhibitor dissociation constant for the target enzyme.\n- Clinical pharmacokinetics constrain maximum safe plasma concentrations. For pyrimethamine, a standard oral regimen achieves a maximum plasma concentration $C_{\\max} \\approx 2\\,\\mu\\text{M}$ under usual dosing in adults. Well-tested biochemical measurements show that wild-type pfDHFR binds pyrimethamine with $K_i \\approx 0.02\\,\\mu\\text{M}$, the S$108$N single mutant increases $K_i$ to approximately $0.3\\,\\mu\\text{M}$, and the N$51$I+C$59$R+S$108$N triple mutant increases $K_i$ to approximately $10\\,\\mu\\text{M}$ while preserving catalytic activity for dihydrofolate reduction. The active metabolite of proguanil (cycloguanil) shares the same pfDHFR binding site and shows parallel $K_i$ shifts with these pfDHFR mutations.\n- Atovaquone inhibits mitochondrial electron transport at cytochrome bc$1$ and is unaffected by pfDHFR genotype but loses efficacy with pfCYTb Y$268$S. Artemisinin derivatives act on parasite proteins via endoperoxide activation and are not directly impacted by pfDHFR or pfCYTb, though K$13$ mutations (e.g., C$580$Y) associate with delayed clearance and necessitate robust partner drugs in artemisinin-based combination therapy (ACT).\n\nBased on these principles and data, choose the best algorithmic approach to therapy selection for this patient’s genotype that both explains why pyrimethamine should be avoided and proposes a rational sequence for selecting an alternative regimen. Which option is most appropriate?\n\nA. Because dihydropteroate synthase (DHPS) is presumed wild-type, use sulfadoxine-pyrimethamine and increase the pyrimethamine dose to overcome resistance; if fever persists, add chloroquine.\n\nB. Avoid antifolates when pfDHFR carries S$108$N with N$51$I and C$59$R, because achievable $C_{\\max}$ yields insufficient inhibitor occupancy; next, check pfCYTb: if Y$268$S is absent (as here), select atovaquone-proguanil or an artemisinin-based combination therapy; if Y$268$S is present, avoid atovaquone-proguanil and choose an ACT with a potent partner drug (e.g., artemether-lumefantrine or dihydroartemisinin-piperaquine), adjusting for any K$13$ mutation to ensure adequate partner drug exposure.\n\nC. Prefer proguanil monotherapy, since proguanil does not share the pyrimethamine binding site and thus remains active despite pfDHFR mutations; reserve ACTs for severe malaria only.\n\nD. Choose chloroquine because antifolate resistance implies restored chloroquine sensitivity; add mefloquine if parasitemia is above $1\\,\\%$.\n\nE. Use dihydroartemisinin-piperaquine only if K$13$ C$580$Y is present; otherwise, sulfadoxine-pyrimethamine remains first-line when DHPS is wild-type, regardless of pfDHFR mutations.", "solution": "The problem statement is internally consistent, scientifically grounded in the principles of molecular biology and pharmacology, and well-posed. It provides specific genetic data, relevant pharmacokinetic and pharmacodynamic parameters, and a clear objective. Therefore, the problem is valid, and a solution can be derived.\n\nThe core task is to devise a rational therapeutic strategy for a patient with uncomplicated *Plasmodium falciparum* malaria based on the parasite's genotype. The provided genetic markers and pharmacodynamic data must be integrated to predict drug efficacy.\n\n**1. Analysis of Genotypic Data and Pharmacodynamic Implications**\n\n*   ***Plasmodium falciparum* dihydrofolate reductase (*pfDHFR*)**: The parasite exhibits the N$51$I, C$59$R, and S$108$N triple mutation. These mutations are in the gene encoding the target enzyme for antifolate drugs like pyrimethamine and cycloguanil (the active metabolite of proguanil).\n    *   The problem provides the inhibitor dissociation constant ($K_i$) for pyrimethamine against the triple-mutant *pfDHFR* as $K_i \\approx 10\\,\\mu\\text{M}$.\n    *   The maximum achievable plasma concentration ($C_{\\max}$) of pyrimethamine is given as $C_{\\max} \\approx 2\\,\\mu\\text{M}$.\n    *   The fraction of enzyme bound by the inhibitor, $f$, is given by the formula $f = \\dfrac{C}{C + K_i}$. At the maximum possible drug concentration, the maximum fractional occupancy is:\n        $$f_{\\max} = \\dfrac{C_{\\max}}{C_{\\max} + K_i} = \\dfrac{2\\,\\mu\\text{M}}{2\\,\\mu\\text{M} + 10\\,\\mu\\text{M}} = \\dfrac{2}{12} = \\dfrac{1}{6}$$\n    *   This corresponds to an occupancy of approximately $16.7\\%$. Such low target occupancy is insufficient for effective enzyme inhibition, predicting clinical failure of pyrimethamine. Since the active metabolite of proguanil, cycloguanil, is stated to have parallel $K_i$ shifts, it too will be ineffective. Therefore, any regimen based on pyrimethamine or proguanil, such as sulfadoxine-pyrimethamine (SP) or atovaquone-proguanil (AP) where proguanil is expected to contribute to cure, is compromised.\n\n*   ***Plasmodium falciparum* cytochrome b (*pfCYTb*)**: The parasite is wild-type at the Y$268$ locus (the Y$268$S mutation is absent).\n    *   The problem states that atovaquone loses efficacy in the presence of the Y$268$S mutation.\n    *   The absence of this mutation implies that the parasite is susceptible to atovaquone.\n\n*   ***Kelch 13* (*K13*)**: The parasite has a wild-type *K13* gene (the C$580$Y mutation is absent).\n    *   The problem states that *K13* mutations are associated with delayed parasite clearance in response to artemisinin derivatives.\n    *   The wild-type status of *K13* indicates that the artemisinin component of any artemisinin-based combination therapy (ACT) will be fully effective, with normal parasite clearance times expected.\n\n*   ***Plasmodium falciparum* multidrug resistance $1$ (*pfMDR1*)**: The copy number is $1$.\n    *   Amplification of the *pfMDR1* gene (copy number $>1$) is associated with resistance to certain drugs like mefloquine and lumefantrine.\n    *   A copy number of $1$ suggests susceptibility to these partner drugs, making ACTs like artemether-lumefantrine and artesunate-mefloquine potentially good choices.\n\n**2. Synthesis of a Rational Therapeutic Algorithm**\n\nBased on the analysis, a logical sequence for selecting therapy is as follows:\n1.  Evaluate antifolate efficacy using the *pfDHFR* genotype. The presence of the N$51$I+C$59$R+S$108$N triple mutation contraindicates the use of pyrimethamine and proguanil due to extremely high resistance ($K_i \\gg C_{\\max}$).\n2.  If antifolates are ruled out, evaluate the next options.\n3.  Check atovaquone susceptibility via the *pfCYTb* genotype. The absence of the Y$268$S mutation indicates susceptibility, making atovaquone-proguanil a viable option, relying solely on the atovaquone component for effect.\n4.  Evaluate ACT suitability. Check the *K13* genotype. The wild-type status confirms full activity of the artemisinin component. Given the *pfMDR1* copy number of $1$, standard partner drugs are likely to be effective. Therefore, WHO-recommended ACTs (e.g., artemether-lumefantrine, dihydroartemisinin-piperaquine) are excellent choices.\n\nThis logical flow allows for the selection of an effective regimen (an ACT or atovaquone-proguanil) while correctly identifying and avoiding a therapy (sulfadoxine-pyrimethamine) that is predicted to fail.\n\n**3. Evaluation of Options**\n\n*   **A. Because dihydropteroate synthase (DHPS) is presumed wild-type, use sulfadoxine-pyrimethamine and increase the pyrimethamine dose to overcome resistance; if fever persists, add chloroquine.**\n    *   This is flawed. The resistance is to pyrimethamine, which targets *pfDHFR*, not sulfadoxine, which targets *DHPS*. The *DHPS* status is not the primary issue. As calculated, the resistance level ($K_i \\approx 10\\,\\mu\\text{M}$) is too high to be overcome by safe dose escalation ($C_{\\max} \\approx 2\\,\\mu\\text{M}$); attempting to do so would risk significant toxicity.\n    *   **Verdict:** Incorrect.\n\n*   **B. Avoid antifolates when pfDHFR carries S$108$N with N$51$I and C$59$R, because achievable $C_{\\max}$ yields insufficient inhibitor occupancy; next, check pfCYTb: if Y$268$S is absent (as here), select atovaquone-proguanil or an artemisinin-based combination therapy; if Y$268$S is present, avoid atovaquone-proguanil and choose an ACT with a potent partner drug (e.g., artemether-lumefantrine or dihydroartemisinin-piperaquine), adjusting for any K$13$ mutation to ensure adequate partner drug exposure.**\n    *   This option perfectly represents the rational algorithm derived above. It correctly identifies the reason for avoiding antifolates (insufficient target occupancy), then proposes a logical decision tree based on other relevant genetic markers (*pfCYTb* and *K13*) to select an appropriate alternative from the main classes of drugs (atovaquone-proguanil or an ACT). This approach is comprehensive and correct.\n    *   **Verdict:** Correct.\n\n*   **C. Prefer proguanil monotherapy, since proguanil does not share the pyrimethamine binding site and thus remains active despite pfDHFR mutations; reserve ACTs for severe malaria only.**\n    *   This is factually incorrect based on the problem statement itself, which explicitly states, \"The active metabolite of proguanil (cycloguanil) **shares the same pfDHFR binding site** and shows parallel $K_i$ shifts\". Thus, proguanil is ineffective. Furthermore, reserving ACTs for severe malaria is contrary to modern treatment guidelines for *P. falciparum*, for which ACTs are the first-line treatment for uncomplicated cases.\n    *   **Verdict:** Incorrect.\n\n*   **D. Choose chloroquine because antifolate resistance implies restored chloroquine sensitivity; add mefloquine if parasitemia is above $1\\,\\%$.**\n    *   This assumes a complex and unstated genetic linkage between antifolate resistance and chloroquine sensitivity, which is not a reliable basis for therapy selection. Chloroquine resistance is widespread and determined by markers such as *pfcrt*, which were not provided. This choice is speculative and not based on the given data.\n    *   **Verdict:** Incorrect.\n\n*   **E. Use dihydroartemisinin-piperaquine only if K$13$ C$580$Y is present; otherwise, sulfadoxine-pyrimethamine remains first-line when DHPS is wild-type, regardless of pfDHFR mutations.**\n    *   This option contains multiple severe errors. It incorrectly dismisses the *pfDHFR* mutations, which are the crux of the problem. It also reverses the logic for using an ACT: the presence of a *K13* mutation is a complication for ACTs, not a prerequisite for their use. ACTs are a primary therapy for drug-resistant malaria, regardless of *K13* status.\n    *   **Verdict:** Incorrect.", "answer": "$$\\boxed{B}$$", "id": "4649201"}]}